

Date: April 26, 2016

To

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051**

Company Code No. AUROPHARMA

То

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001**

Company Code No. 524804

Dear Sirs.

SUB: Press Release - Reg

We enclose copy of the Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

A.MOHAN RAMI REDDY

Vice President (Legal) & Company Secretary





NEWS RELEASE 26th April 2016, Hyderabad, India

Aurobindo Pharma receives USFDA Approval for Amlodipine and Valsartan Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Amlodipine and Valsartan Tablets USP, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg. This product is expected to be launched in Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exforge® Tablets of Norvartis Pharmaceuticals Corporation.

Amlodipine and Valsartan Tablets are used in the treatment of hypertension, to lower blood pressure. The approved product has an estimated market size of US\$ 123 million for the twelve months ending February 2016 according to IMS.

This is the 71st ANDA (including 15 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 254 ANDA approvals (218 Final approvals including 10 from Aurolife Pharma LLC and 36 tentative approvals) from USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Investor Relations

Phone: 040-66725401 / 66725000,

Mobile: +91 98486 67906 Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential—and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN:L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059 Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 088 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com